Overview / Abstract: |
The role of the multidisciplinary transplant team has expanded considerably over the past decade to keep pace with advances in the field and to address long-term care of transplant recipients. Despite these advances, breakthrough cytomegalovirus (CMV) infections and development of refractory and resistant CMV infections cause significant complications post-transplant. To lessen patient burden and improve survival outcomes, optimal introduction of anti-CMV drugs, both prophylactically and therapeutically is critical. To address these needs, this education offers personalized education with nuanced pathways applicable to solid organ and hematopoietic stem cell transplant (HSCT) settings. Learners will complete a brief assessment to inform targeted areas of educational need and then be able to build their own customized slide deck, allowing them to bypass areas of established knowledge and focus on areas of greatest interest or relevance to their clinical practice. |
Expiration |
Jul 08, 2025 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
Format |
Online, Performance Improvement |
Credits / Hours |
Up to 2.75 AMA PRA Category 1 Credit(s) & 2.0 ACPE contact hours |
Accreditation |
ACCME, ACPE |
Is This Activity Certified for "Live" Credit? |
YES |
Presenters / Authors / Faculty |
Fernanda P. Silveira, MD, MS, FIDSA, FAST (Chair) Roy F Chemaly, MD, MPH, FIDSA, FACP Raymund R. Razonable, MD |
Sponsors / Supporters / Grant Providers |
Supported by an educational grant from Merck & Co., Inc.. |
Keywords / Search Terms |
ACHL Cytomegalovirus, CMV, solid organ transplant, SOT, hematopoietic stem cell transplant, HSCT, post-transplant, HCT, kidney transplant, CMV infection, CMV disease, end-organ disease, ganciclovir, valganciclovir, foscarnet, cidofovir, letermovir, maribavir, pre-emptive therapy, PET, prophylaxis, resistant/refractory CMV, R/R CMV, resistance, serostatus Free CE CME Live CE CME |